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ABSTRACT
The impact of rheumatic disease on fertility and
reproduction can be remarkable. Many disease-related
factors can influence patients’ sexual functioning,
perturb fertility and limit family planning. Antirheumatic
pharmacological treatment can also have a crucial role
in this field. Proper counselling, preferably provided by
a multidisciplinary team of rheumatologists,
obstetricians, gynaecologists and neonatologists, is
recommended for patients taking antirheumatic drugs,
not only at the beginning, but also during the course
of treatment. Paternal exposure to antirheumatic drugs
was not found to be specifically associated with
congenital malformation and adverse pregnancy
outcome, therefore discontinuation of these drugs
while planning for conception should be weighed
against the risk of disease flare. Drugs in Food and
Drug Administration (FDA) category ‘X’ should be
withdrawn in a timely manner in women who desire a
pregnancy. Meanwhile, disease control can be achieved
with anti-tumour necrosis factor (TNF)-α agents, which
are not teratogenic drugs. If maternal disease control is
permissive, they can be stopped as soon as the
pregnancy test turns positive and be resumed during
pregnancy in case of a flare.
INTRODUCTION
Rheumatic diseases can inﬂuence quality of
life of affected patients by interfering with a
number of aspects, including sexuality and
reproduction. The purpose of this brief
review is to analyse the possible effects of
antirheumatic drugs on fertility and repro-
duction in rheumatic patients affected by
chronic arthritis, with particular focus on bio-
logical treatments. This is a concise overview
of the topics presented at the International
Congress ‘Osteorheumatology 2014’, orga-
nised in Genova, Italy, in October 2014.
FERTILITY
Women with rheumatic diseases have a lower
number of births, a reduced period of repro-
duction and a longer inter-pregnancy interval
with difﬁculties in achieving subsequent preg-
nancy, in comparison with healthy controls.1
The reasons for impaired sexual functioning
and reproduction in rheumatic patients are
complex and multifactorial. Some problems
can be related directly to the disease process
itself. Rheumatic symptoms such as chronic
pain, fatigue, stiffness and impaired joint
function can reduce libido and limit sexual
satisfaction. Hormonal disorders, pelvic
organ involvement and autoimmunity disor-
ders can decrease patients’ fecundity, and
preclude successful pregnancy. Psychological
problems (isolation, depression, anxiety),
usually related to chronic and disabling
disease, can limit interpersonal dynamics,
and negatively inﬂuence sexual relationships
and family planning.2 Among factors that are
directly disease-related, high disease activity is
one of the most important aspects and may
contribute essentially both to the longer time
to conceive and worse pregnancy outcome in
women affected by rheumatoid arthritis.3
Interactions between other kinds of chronic
inﬂammatory arthritis (ankylosing spondylitis,
Key messages
What is already known about this subject?
▸ Rheumatic diseases can interfere with reproduc-
tion. The approach to reproductive problems
and pregnancy management in rheumatic
patients represents a great challenge.
What does this study add?
▸ The purpose of this brief paper is to review the
possible effects of antirheumatic drugs on fertil-
ity and reproduction in rheumatic patients
affected by chronic arthritis, with particular
focus on biological treatments.
How might this impact on clinical practice?
▸ Interdisciplinary approach and proper counseling
with more effective physician-patient communi-
cation about family planning and desire for preg-
nancy should be encouraged to optimize
pregnancy outcomes.
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psoriatic arthritis, juvenile idiopathic arthritis) and fertil-
ity or pregnancy have been less investigated than those in
rheumatoid arthritis. In spite of this fact, decreased
fecundity (but not infertility) seems to characterise these
patients as well.4 5
DISEASE ACTIVITY DURING PREGNANCY
Previous retrospective studies, mainly based on patients’
self-reports and conducted in a period of limited treat-
ment options, demonstrated that disease activity
improved during pregnancy in the majority of women
affected by rheumatoid arthritis.6 More recently, pro-
spective studies have shown that these patients not only
achieve disease remission during pregnancy less fre-
quently, but also have less improvement in disease activ-
ity during pregnancy than previously thought.7 8 In
2008, de Man et al7 showed that the proportion of
women with at least moderate disease activity (DAS
28>3,2) during pregnancy was about 40%. During the
third trimester, only 27% were in complete remission
(DAS 28<2.6) and consequently had a signiﬁcant
reduction in drug prescriptions. During post-partum
period, 39% of women had increased disease activity
but only 4% had a severe ﬂare. No profound effect of
pregnancy on ankylosing spondylitis disease activity
was described, even if some prospective studies
proved disease worsening during the ﬁrst and early
second trimester of gestation and after delivery.9 10
Few papers are published about the course of psori-
atic arthritis during gestation. Available reports seem
to support an amelioration of disease activity during
pregnancy.11
PREGNANCY OUTCOME
Several studies have demonstrated a slight increase in
obstetric complications in women affected by chronic
arthritis. While a high frequency of miscarriages is not
observed, some reports revealed an increased prevalence
of small for gestational age infants, preterm delivery and
caesarean sections in these patients.12 13 In some studies
conducted in rheumatoid arthritis patients, an increased
rate of pre-eclampsia was observed.14 15 Adverse preg-
nancy outcomes, in particular low birth weight, seem to
be directly related to a higher level of disease activity,
even if birth weight could also be indirectly inﬂuenced
by the use of prednisone, through the promotion of a
lower gestational age.16
ANTIRHEUMATIC TREATMENTS AND PREGNANCY
IN CHRONIC ARTHRITIS PATIENTS
Disease modifying antirheumatic drugs and maternal
exposure
Although some women affected by chronic arthritis
sometimes have a transient reduction in disease activity
and arthritis symptoms during pregnancy, treatment with
antirheumatic drugs is frequently required during
gestation.7 17 So, while planning a pregnancy, it is import-
ant to choose a treatment that is effective in controlling
disease activity, but that does not affect fertility nor fetal
health. Most antirheumatic drugs have no effect on the
gonads, however, as shown in table 1, they can sometimes
cause fertility disorders or induce an increased risk of
malformations/complications in newborns. The ﬁrst step
in the management of patients desiring pregnancy is the
timely withdrawal of teratogenic medications. For a long
time, methotrexate and leﬂunomide, the most widely
used disease modifying antirheumatic drugs (DMARDS)
in arthritis patients, have been investigated for their
potential teratogen effect. To date, the use of these drugs
during the preconception period and pregnancy has
been contraindicated in women as well as in men and
therefore safe contraception is strongly recommended to
patients taking these medications.18 However, recent
studies have shed light on the teratogenic potential of
these drugs. Even though preclinical animal studies
suggest that leﬂunomide could be a human teratogen,
the results of two studies conducted by the Organization
of Teratology Information Specialists (OTIS) have not
demonstrated an increase in the rate of major birth
defects in children of women treated with leﬂunomide
during the ﬁrst trimester of gestation or in the precon-
ception period.19 20 In these two studies, most of the
patients (75% and 95%, respectively) underwent choles-
tyramine washout procedure after leﬂunomide with-
drawal.19 20 Methotrexate is a potent teratogen when
used at high doses for cancer treatment, but its fetotoxic
effect when administered at a low weekly dose according
to rheumatologic practice is still not well deﬁned.21
A study published in 2014 described an increased risk of
major birth defects and spontaneous abortion in women
exposed to methotrexate, at dosages typically used in
rheumatic patients, only in the postconception period,
while no abnormalities were noted in women exposed
before conception.22 For its potential embryotoxicity and
teratogenicity in animal and human pregnancy, metho-
trexate discontinuation is suggested 3–6 months before
conception.23
DMARDs and paternal exposure
Preconception exposure to DMARDs in male patients
has been suspected to be a risk factor for babies’ health.
However, recent studies have been reassuring about the
lack of negative inﬂuence of DMARDs on offspring after
paternal exposure. One study excluded an increased risk
of adverse pregnancy outcome after paternal low-dose
methotrexate therapy and the authors concluded that a
3-month MTX-free interval until conception is probably
not necessary in male patients.28 A longitudinal observa-
tional study proved that preconception paternal expos-
ure to DMARDs in the 12 weeks prior to conception was
not associated with increased adverse pregnancy
outcome.29 Some drugs can impair men’s fertility; this is
the case with sulphasalazine (SSZ). Animal reproductive
studies with SSZ and a population-based case–control
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study demonstrated no signiﬁcant increase in female
infertility or in congenital abnormalities in newborns.30
However, treatment with SSZ can lead to infertility in
men and male rats, inducing oligospermia, reduced
sperm motility, and increased seminal abnormalities.31
The effect cannot be reduced by folate supplementa-
tion, but spermatogenesis improves about 2 months after
withdrawal of the drug.31 Proper counselling should be
offered to male patients trying to outweigh the risk of
disease ﬂare on drug withdrawal against the impact of
the drug on reproduction.
Tumour necrosis factor (TNF)-α inhibitors
While the relationship between DMARDs and their
impact on reproduction has always been intriguing, in
recent times, more attention has been devoted to the
effects of biological antirheumatic drugs on fertility and
pregnancy. Thanks to the widespread use of these
Table 1 Antirheumatic drugs and risk during pregnancy (modified and updated from Hazes et al23)
Drug class FDA category
Effects on pregnancy
or exposed babies
Clinical recommendations
in female patients
NSAIDs B (in early
stage of
pregnancy)
C (after week
30)
Late in pregnancy can cause premature
closure of the ductus arteriosus,
increase the risk of neonatal bleeding,
impairment of fetal renal function and
development of oligohydramnios
Compatible with pregnancy in first half of
the pregnancy23
STEROIDS C In doses >10 mg/day during pregnancy
they can have adverse side effects both
on mothers (diabetes, hypertension,
osteopaenia, infections) and fetuses
(prematurity, low birth weight, IUGR,
infections, adrenal suppression,
oral cleft)
Compatible with pregnancy in doses up to
10–15 mg/day (prednisolone
equivalent)23 24
METHOTREXATE X Potential embryotoxicity and
teratogenicity in animal and human
pregnancy
Discontinuation 3–6 months before
conception23
LEFLUNOMIDE X Potential embryotoxicity and
teratogenicity in animal and human
pregnancy
Discontinue 2 years before pregnancy or
use cholestyramine washout procedure23
SULFASALAZYNE B No increase in malformation in human
pregnancy
Compatible with pregnancy;Folate
supplements needed23
ANTIMALARIALS C Malformations of the inner ear after
treatment with higher than the
recommended dose of chloroquine25
Hydroxychloroquine compatible with
pregnancy23
CYCLOSPORIN A C Increase in premature delivery and low
birth weight, but no increase of
congenital malformations
Compatible with pregnancy in patients with
autoimmune disease refractory to other
immunosuppressive treatment26
AZATHIOPRINE D No increase in malformation in human
pregnancy; potential teratogenicity in
animal models
Compatible with pregnancy23
TNFa
INHIBITORS
B No increase in miscarriage or birth
defects
Discontinuation after pregnancy detection.
If used during pregnancy, they should be
discontinued before gestational week 3024
ABATACEPT C No conclusive human data Discontinuation 3 months before
conception24
TOCILIZUMAB C No conclusive human data Discontinuation 3 months before
conception24
RITUXIMAB C No increase in miscarriage or
malformation. Exposure during the
second and third trimesters possibly
causes B cell depletion in the fetus
Discontinuation 12 months before
conception27
ANAKINRA B Animal data: no harm in offspring.
No conclusive human data
Discontinuation after pregnancy detection24
The US FDA pregnancy risk categories are as follows: A, no risk in controlled clinical studies in humans; B, animal studies show no risk and
human data is reassuring even if well-controlled studies of pregnant women have not been conducted; C, human data are lacking and animal
studies show risk (or have not been undertaken); D, positive evidence of human fetal risk: use only if potential benefit outweighs the risk; X,
studies in animals or reports of adverse reactions show positive evidence of risk: contraindication during pregnancy.
FDA, Food and Drug Administration; NSAIDs, nonsteroidal anti-inflammatory drugs; TNF, tumour necrosis factor.
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potent drugs in the past 10 years, a great improvement
in patients’ quality of life has induced a better percep-
tion of social needs such as family planning. An increas-
ing number of affected women ask their rheumatologists
about the possibility of having a baby and continue their
biological antirheumatic treatment during gestation as
well. Tumour necrosis factor (TNF)-α inhibitors, the ﬁrst
introduced and most studied antirheumatic biological
drugs, do not impair fertility in men,32 33 and seem to
be potential therapeutic agents for treating some types
of female infertility, such as endometriosis.34 Although
randomised studies in pregnant women have not been
conducted owing to ethical issues, anti-TNF-α drugs are
not considered fetotoxic (Food and Drug
Administration, FDA pregnancy category B),35 in agree-
ment with the results of preclinical studies. The pub-
lished experience mainly consists of preclinical/animal
reproduction studies, case reports from inadvertent drug
exposure during pregnancy, registries and large observa-
tional studies of pregnant patients with arthritis or
inﬂammatory bowel disease.26 36 In the absence of ran-
domised controlled trials, the manufacturers of TNF-α
inhibitors advise discontinuing these agents before a
planned pregnancy. In fact, most biologic agents are
complete IgG antibodies or IgG-derived-molecules that
can be actively transferred through the placenta by
Fc-receptors. This active transplacental transport signiﬁ-
cantly changes according to the different structural fea-
tures of biological compounds and is more effective for
complete monoclonal antibodies.23 The transport gener-
ally starts at the beginning of the second trimester and
increases until term,37 when maternal and fetal drug
serum levels can be equal, or concentrations in cord
blood even higher.38 So, if fetal exposure to IgG-drugs is
very low in the ﬁrst trimester during organogenesis, it
can be more relevant when drugs are administered in
the second part of gestation. In the past few years,
numerous new pregnancies, with a ﬁrst trimester expos-
ure to these drugs, have been reported with a good
pregnancy outcome.24 According to the majority of the
experts, anti-TNF-α agents can be considered safe in the
early stage of pregnancy. If maternal disease is in remis-
sion, the treatment could be discontinued after the
pregnancy test turns positive in order to limit the trans-
placental passage of the drug. On the other hand, some
patients who discontinued the treatment in the early
stages of pregnancy need to resume it during gestation
because of severe disease ﬂares. In these cases, to avoid
an impaired immune response and a higher infective
risk in the babies, TNF-α inhibitors should be discontin-
ued at latest at gestational week 30, especially if they are
complete monoclonal antibodies.24 In a study assessing
the course of inﬂammatory bowel disease in pregnant
women, the authors demonstrated that cord blood con-
centrations of inﬂiximab were lower among women who
received the drug 10 weeks or less before delivery than
those treated closer to it.39 In our experience, between
1999 and 2013, we identiﬁed 74 exposed pregnancies in
women affected by different rheumatic diseases with per-
ipheral chronic arthritis and treated with TNF-α inhibi-
tors.40 Biological treatment was stopped after a mean of
41 days since documented pregnancy. Live births were
reported in 66% (49/74) of pregnancies. In our cohort,
spontaneous abortion and fetal death rate was 15% and
7%, respectively. The same proportion was observed in
retrospective studies about TNF-α use in pregnancy41
and in the general population as well.42 Elective termin-
ation was performed in 7 women (9%), with a higher
rate in the group of patients exposed to biological agent
plus methotrexate or leﬂunomide and with lower mater-
nal age. We observed neither a high rate of malforma-
tions (2%) nor any relevant obstetric or neonatal
adverse events. Six pregnancies were exposed to TNF-α
inhibitors in the second/third trimester, because of high
maternal disease activity. All these cases ended in live
births. No fetal/neonatal complications were noted also
in this subgroup of pregnancies and in particular
no infectious events were reported in the newborns.
In agreement with previously published data, our study
concluded that women who inadvertently become preg-
nant while taking TNF-α inhibitors should be reassured
that continuation of pregnancy does not represent a risk
of negative obstetric or neonatal outcomes.
Other biological drugs
Published data about biological agents other than TNF-α
inhibitors during pregnancy is limited. Some information
comes from the rituximab global drug safety database. It
includes data about more than 200 pregnancies occurring
before 2009 in women affected by malignant diseases or
different types of autoimmune diseases and treated with
rituximab, the IgG1 monoclonal antibody with B-cell–
depleting function.27 The analysis of 153 pregnancies with
known outcomes demonstrates no excess of neonatal
deaths or congenital birth defects. Few neonatal infections
or haematological abnormalities were seen among
exposed babies.27 Although no severe complications
were observed, women are recommended to delay preg-
nancy for at least 12 months after rituximab exposure.
Experience of pregnancy exposure to abatacept,43 tocilizu-
mab44 and anakinra45 46 has largely been limited to confer-
ence abstracts or simple case reports. Owing to insufﬁcient
experience, no conclusion can be drawn on the compati-
bility of these drugs with pregnancy.
LONG-TERM FOLLOW-UP OF EXPOSED BABIES
At present, no statement about long-term safety of bio-
logical drugs administered during gestation can be made,
given that the long-term follow-up of the exposed babies
has not been fully assessed. Few data are currently avail-
able on the health, development, immune competence
and infection susceptibility of the exposed infants. An
uncontrolled study published in 2014 on 25 babies
exposed to anti-TNFs prenatally for maternal inﬂamma-
tory bowel disease demonstrated normal growth and
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psychomotor development, and a relatively high fre-
quency of infections, among infants.47 We obtained
similar results in a case–control study that investigates the
health and developmental conditions of 21 children who
were exposed in utero to anti-TNF-α agents in compari-
son with 21 non-exposed children born to mothers with
the same rheumatic disease. Data about the babies’ clin-
ical conditions are derived by an ad-hoc created question-
naire submitted to the mothers. Our preliminary data
demonstrate that children exposed in utero to
anti-TNF-α drugs display good birth outcome, and
normal growth and response to vaccinations. Infectious
disorders are reported in the ﬁrst year of life but with a
benign course, and no signiﬁcant differences between
exposed and non-exposed children were noted (L
Andreoli, C Bazzani, M Agosti, et al; personal communica-
tion. Long-term follow-up of children born to mothers
with Chronic Arthritides and exposed in utero to
anti-TNFalfa agents: a case–control study. 8th
International Conference on Reproduction, Pregnancy
and Rheumatic Diseases; 25–27 September 2014,
Trondheim, Norway). In order to draw conclusions, these
ﬁndings have to be veriﬁed in a larger cohort.
CONCLUSION
The approach to reproductive problems and pregnancy
management in rheumatic patients represents a great chal-
lenge. The turning point is represented by preconception
counselling. Optimising pregnancy outcomes is based on
informing male and female patients about potential risks
related to the disease, planning for pregnancy during a
period of clinical remission or, at least, low disease activity,
and ensuring that ongoing treatments are both effective
and compatible with pregnancy. TNF-α inhibitors can be
considered safe while seeking for conception and in the
ﬁrst part of gestation, representing a possible therapeutic
choice in patients affected by aggressive forms of chronic
arthritis and desiring to have a baby. An interdisciplinary
approach with the cooperation of rheumatologists, obste-
tricians, gynaecologists and neonatologists is crucial before
and during pregnancy, and more effective physician-
patient communication about family planning and desire
for pregnancy should be reached. A prospective collection
of additional exposures and new multicentric follow-up
studies investigating perinatal infections, vaccination
responses and global development of children is obviously
needed to conﬁrm the safety of antenatal exposure to anti-
rheumatic biological drugs.
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